OBJECTIVE: Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks. RESEARCH DESIGN AND METHODS: Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients. The primary end point was change in hemoglobin A1c (HbA1c). Outcomes are reported adhering to consensus recommendations on reporting of AP trials. RESULTS: Twenty-nine patients completed the trial. HbA1c, 7.0 ± 0.8% at the start of AP use, improved to 6.7 ± 0.6% after 12 weeks (-0.3, 95% CI -0.5 to -0.2, P < 0.001). Compared with the SAP run-in, CGM time spent in the hypoglycemic range improved during the day from 5.0 to 1.9% (-3.1, 95% CI -4.1 to -2.1, P < 0.001) and overnight from 4.1 to 1.1% (-3.1, 95% CI -4.2 to -1.9, P < 0.001). Whereas carbohydrate ratios were adapted to a larger extent initially with minimal changes thereafter, basal insulin was adapted throughout. Approximately 10% of adaptation recommendations were manually overridden. There were no protocol-related serious adverse events. CONCLUSIONS: Use of our novel adaptive AP yielded significant reductions in HbA1c and hypoglycemia.
OBJECTIVE: Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks. RESEARCH DESIGN AND METHODS: Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients. The primary end point was change in hemoglobin A1c (HbA1c). Outcomes are reported adhering to consensus recommendations on reporting of AP trials. RESULTS: Twenty-nine patients completed the trial. HbA1c, 7.0 ± 0.8% at the start of AP use, improved to 6.7 ± 0.6% after 12 weeks (-0.3, 95% CI -0.5 to -0.2, P < 0.001). Compared with the SAP run-in, CGM time spent in the hypoglycemic range improved during the day from 5.0 to 1.9% (-3.1, 95% CI -4.1 to -2.1, P < 0.001) and overnight from 4.1 to 1.1% (-3.1, 95% CI -4.2 to -1.9, P < 0.001). Whereas carbohydrate ratios were adapted to a larger extent initially with minimal changes thereafter, basal insulin was adapted throughout. Approximately 10% of adaptation recommendations were manually overridden. There were no protocol-related serious adverse events. CONCLUSIONS: Use of our novel adaptive AP yielded significant reductions in HbA1c and hypoglycemia.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: Fraser Cameron; Günter Niemeyer; Darrell M Wilson; B Wayne Bequette; Kari S Benassi; Paula Clinton; Bruce A Buckingham Journal: Diabetes Technol Ther Date: 2014-09-26 Impact factor: 6.118
Authors: H Thabit; M Tauschmann; J M Allen; L Leelarathna; S Hartnell; M E Wilinska; C L Acerini; S Dellweg; C Benesch; L Heinemann; J K Mader; M Holzer; H Kojzar; J Exall; J Yong; J Pichierri; K D Barnard; C Kollman; P Cheng; P C Hindmarsh; F M Campbell; S Arnolds; T R Pieber; M L Evans; D B Dunger; R Hovorka Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Hood Thabit; Alexandra Lubina-Solomon; Marietta Stadler; Lalantha Leelarathna; Emma Walkinshaw; Andrew Pernet; Janet M Allen; Ahmed Iqbal; Pratik Choudhary; Kavita Kumareswaran; Marianna Nodale; Chloe Nisbet; Malgorzata E Wilinska; Katharine D Barnard; David B Dunger; Simon R Heller; Stephanie A Amiel; Mark L Evans; Roman Hovorka Journal: Lancet Diabetes Endocrinol Date: 2014-06-16 Impact factor: 32.069
Authors: Jordan E Pinsker; Alejandro J Laguna Sanz; Joon Bok Lee; Mei Mei Church; Camille Andre; Laura E Lindsey; Francis J Doyle; Eyal Dassau Journal: Diabetes Technol Ther Date: 2018-07 Impact factor: 6.118
Authors: Elliott W Dirr; Morgan E Urdaneta; Yogi Patel; Richard D Johnson; Martha Campbell-Thompson; Kevin J Otto Journal: Bioelectron Med (Lond) Date: 2020-07-28
Authors: Stacey M Anderson; Eyal Dassau; Dan Raghinaru; John Lum; Sue A Brown; Jordan E Pinsker; Mei Mei Church; Carol Levy; David Lam; Yogish C Kudva; Bruce Buckingham; Gregory P Forlenza; R Paul Wadwa; Lori Laffel; Francis J Doyle; J Hans DeVries; Eric Renard; Claudio Cobelli; Federico Boscari; Simone Del Favero; Boris P Kovatchev Journal: Diabetes Technol Ther Date: 2019-01-16 Impact factor: 6.118